 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Alnylam Pharmaceuticals
ALNY
conference date: October 31, 2024 @ 5:30 AM Pacific Time
Alnylam: Potential Is In Line With Current Valuation by William Meyers [October 7, 2021 Seeking Alpha]
Alnylam's RNA Therapies Make It A Buy by William Meyers [November 28, 2020 Seeking Alpha]
Alnylam as a Strategic Investment by William Meyers [February 21, 2019 Seeking Alpha]
Alnylam: Fully Priced, But A Future Star by William Meyers [August 21, 2018 Seeking Alpha]
Analyst Conference Notes by William P. Meyers |
|||
| 2024 | |||
| Alnylam Q1 2024 |
Alnylam Q2 2024 |
Alnylam Q3 2024 |
|
| May 2, 2024 | Aug. 1, 2024 | Oct. 31, 2024 | |
| 2023 | |||
| Alnylam Q1 2023 |
Alnylam Q2 2023 |
Alnylam Q3 2023 |
Alnylam Q4 2023 |
| May 4, 2023 | Aug. 3, 2023 | Nov. 2, 2023 | Feb. 15, 2024 |
| 2022 | |||
| Alnylam Q1 2022 |
Alnylam Q2 2022 |
Alnylam Q3 2022 |
Alnylam Q4 2022 |
| April 28, 2022 | July 28, 2022 | Oct. 27, 2022 | Feb. 23, 2023 |
| 2021 | |||
| Alnylam Q1 2021 |
Alnylam Q2 2021 |
Alnylam Q3 2021 |
Alnylam Q4 2021 |
| April 29, 2021 | August 3, 2021 | Oct. 28, 2021 | Feb. 10, 2022 |
| 2020 | |||
| Alnylam Q1 2020 |
Alnylam Q2 2020 |
Alnylam Q3 2020 |
Alnylam Q4 2020 |
| May 6, 2020 | Aug. 6, 2020 | Nov. 5, 2020 | Feb. 11, 2021 |
| 2019 | |||
| Alnylam Q1 2019 |
Alnylam Q2 2019 |
Alnylam Q3 2019 |
Alnylam Q4 2019 |
| May 1, 2019 | August 6, 2019 | Oct. 31, 2019 | Feb. 6, 2020 |
2018 |
|||
| Alnylam Q4 2018 |
|||
May 3, 2018 |
August 2, 2018 |
Nov. 7, 2018 |
Feb. 7, 2019 |
2017 |
|||
May 5, 2017 |
August 9, 2017 |
Nov. 7, 2017 |
Feb. 8, 2018 |
2016 |
|||
05/02/2016 |
08/04/2016 |
11/02/2016 |
02/08/2017 |
2015 |
|||
05/07/2014 |
08/06/2015 |
11/09/2015 |
02/11/2016 |
Alnylam Readouts Offer Catalysts for 2017-2018 [June 24, 2016 Seeking Alpha]
Why Alnylam Should Be a Big Mover in 2016 [December 8, 2015 at Seeking Alpha]
Is Alnylam in 2020 Worth $9 Billion Now? [April 28, 2015 at Seeking Alpha]
Alnylam Pharmaceuticals (ALNY) is a clinical-stage developer of RNAi based therapies.
I sold my remaining ALNY stock on October 9, 2017. I may buy again if the stock price or developments make it attractive, by my standards, again.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CDTX |
| CLDX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| IONS |
| MCHP |
| MRNA |
| REGN |
| RNA |
| SAGE |
| SANA |
| SYRS |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2024 William P. Meyers